Novobismol

Active substances:

bismuth tripotassium dicitrate 304.6 mg, which corresponds to the content of bismuth oxide 120 mg; 

Excipients: 

corn starch - 70.6 mg,

povidone K 30 - 17.7 mg,

potassium polyacrylate - 23.6 mg,

macrogol 6000 - 6.0 mg

magnesium stearate - 2.0 mg

Novobismol is an anti-ulcer agent with bactericidal activity against Helicobacter pylori.

It also has anti-inflammatory and astringent effects.

In the acidic environment of the stomach, it forms insoluble bismuth oxychloride and citrate, as well as chelating compounds with a protein substrate in the form of a protective film on the surface of ulcers and erosion.

Increasing the synthesis of prostaglandin E, the formation of mucus and the secretion of bicarbonate, stimulates the activity of cytoprotective mechanisms, increases the resistance of the gastrointestinal mucosa to the effects of pepsin, hydrochloric (hydrochloric) acid, enzymes and bile salts.

It leads to the accumulation of epidermal growth factor in the defect zone.

Reduces the activity of pepsin and pepsinogen.

Peptic ulcer of the stomach and duodenum in the exacerbation phase (including those associated with Helicobacter pylori);

chronic gastritis and gastroduodenitis in the acute phase (including associated with Helicobacter pylori);

irritable bowel syndrome, occurring mainly with symptoms of diarrhea;

functional dyspepsia, not associated with organic diseases of the gastrointestinal tract.

Use during pregnancy and during lactation (breastfeeding) is contraindicated.

Severe renal impairment, pregnancy, lactation, hypersensitivity to bismuth tripotassium dicitrate.

From the digestive tract: nausea, vomiting, frequent stools, constipation.

Allergic reactions: skin rash, itching.

Other: with prolonged use in high doses - encephalopathy associated with the accumulation of bismuth in the central nervous system.

While taking other drugs, as well as food and liquids, in particular, antacids, milk, fruits and fruit juices, a change in the effectiveness of bismuth tripotassium dicitrate is possible.

Adults and children over 4 years of age - inside 2-4 times a day 30 minutes before meals. The dose of Novobismol depends on the age of the patient.

The course of treatment is 4-8 weeks. Over the next 8 weeks, bismuth-containing preparations should not be taken.

For the eradication of Helicobacter pylori, it is advisable to use bismuth tripotassium dicitrate in combination with antibacterial drugs with anti-Helicobacter pylori activity.

Novobismol should not be used for more than 8 weeks.

During treatment, it is not recommended to exceed the established daily doses for adults and children.

At the end of the course of treatment in recommended doses, the concentration of the active substance in the blood plasma does not exceed 3-58 μg / L, and intoxication is observed only at a concentration of more than 100 μg / L.

Against the background of application, stool may be stained black due to the formation of bismuth sulfide.

Sometimes a slight darkening of the tongue is noted.

Tablets